JP2023515675A5 - - Google Patents
Info
- Publication number
- JP2023515675A5 JP2023515675A5 JP2022552573A JP2022552573A JP2023515675A5 JP 2023515675 A5 JP2023515675 A5 JP 2023515675A5 JP 2022552573 A JP2022552573 A JP 2022552573A JP 2022552573 A JP2022552573 A JP 2022552573A JP 2023515675 A5 JP2023515675 A5 JP 2023515675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kit
- use according
- administered
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985500P | 2020-03-05 | 2020-03-05 | |
| US62/985,500 | 2020-03-05 | ||
| PCT/US2021/020858 WO2021178657A1 (en) | 2020-03-05 | 2021-03-04 | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515675A JP2023515675A (ja) | 2023-04-13 |
| JP2023515675A5 true JP2023515675A5 (https=) | 2024-03-11 |
Family
ID=77614229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552573A Pending JP2023515675A (ja) | 2020-03-05 | 2021-03-04 | Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230118596A1 (https=) |
| EP (1) | EP4114464A4 (https=) |
| JP (1) | JP2023515675A (https=) |
| KR (1) | KR20220149740A (https=) |
| CN (1) | CN115443152A (https=) |
| WO (1) | WO2021178657A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021344849A1 (en) * | 2020-09-15 | 2023-05-25 | Eisai R&D Management Co., Ltd. | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer |
| CN118660720A (zh) * | 2022-02-22 | 2024-09-17 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| WO2024248535A1 (ko) * | 2023-06-02 | 2024-12-05 | 아주대학교산학협력단 | 글리세롤 탈수효소 변이체 및 이의 용도 |
| KR20260047513A (ko) * | 2023-06-30 | 2026-04-08 | 머크 샤프 앤드 돔 엘엘씨 | 접합체를 포함하는 제약 조합물의 치료방법 및 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| KR102662228B1 (ko) * | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
| JP2021513540A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| EP3793557A1 (en) * | 2018-05-14 | 2021-03-24 | Merck Sharp & Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| WO2021023117A1 (zh) * | 2019-08-02 | 2021-02-11 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
-
2021
- 2021-03-04 US US17/801,409 patent/US20230118596A1/en active Pending
- 2021-03-04 JP JP2022552573A patent/JP2023515675A/ja active Pending
- 2021-03-04 KR KR1020227034434A patent/KR20220149740A/ko active Pending
- 2021-03-04 WO PCT/US2021/020858 patent/WO2021178657A1/en not_active Ceased
- 2021-03-04 CN CN202180028866.1A patent/CN115443152A/zh active Pending
- 2021-03-04 EP EP21764706.4A patent/EP4114464A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515675A5 (https=) | ||
| TWI780083B (zh) | 抗pd-1抗體及組成物 | |
| JP2023510199A5 (https=) | ||
| JP2018070648A5 (https=) | ||
| AU2019210648A1 (en) | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof | |
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2021513540A5 (https=) | ||
| JP2014511179A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| US11939381B2 (en) | Bispecific antibodies targeting immune checkpoints | |
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| RU2011103125A (ru) | КОМБИНАЦИЯ АНТАГОНИСТА c-Met И АМИНОГЕТЕРОАРИЛА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| JP2019524714A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| JP2022543062A5 (https=) | ||
| KR20160111001A (ko) | 암에 대한 조합 요법 | |
| JP2023522630A (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| CN119173277A (zh) | 包含sting激动剂的抗体药物缀合物、组合及使用方法 | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| EP3145544A1 (en) | Ang2 antibodies | |
| JP2021518348A5 (https=) | ||
| WO2022125378A2 (en) | Combination therapy | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| JP2023500480A5 (https=) |